Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
← catalyst calendarNCT07249320 · readout in 407 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-01 | actual | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Virus (RSV)
Intervention
- Biological: ABRYSVO
Primary outcome
what the primary-completion date above is the date OFPolymerase chain reaction (PCR)-confirmed RSV LRTD occurring ≤180 days after birth (first episode).
measured ≤180 days after birth
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed